The Bladder Cancer Patient Journey

Rohit Jain, MD, MPH provides an overview of metastatic bladder cancer, discussing differences in urothelial carcinoma based on location, patient presentations, diagnosis, and staging.

Shared patient perspectives and conversation centered around collaboration in clinical care for metastatic bladder cancer, including the oncology pharmacists’ role in treatment decisions.

Dr Jain discusses frontline treatment options, cisplatin eligibility criteria, and therapy considerations for metastatic bladder cancer.

Mr. Ehas shares his initial treatment experience and response to chemo, while Anand Shah, PharmD, BCOP describes an oncology pharmacists’ role in patient education and adverse event management.

Dr Jain discusses latest data in frontline and maintenance therapy for metastatic bladder cancer and Mr. Ehas shares his experiences during the course of his treatment.

Focusing on immunotherapy management for metastatic bladder cancer, Dr Shah shares notable toxicities, relevant real-world data, and emergent data on maintenance therapy.

Drs Jain and Shah discuss the future of patient care in metastatic bladder cancer, while Mr. and Mrs. Ehas share advice for patients with bladder cancer, advice for caregivers and closing thoughts on their overall journey.

A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.